Table 3.
Immunotherapy in monotherapy for the treatment of recurrent ovarian cancer
| Trial name/identification | Phase | Treatment(s) | Disease setting | Sample size | Follow-up (median months) | Objective response rate (%) |
Progression-free survival (median months) |
Overall survival (median months) |
| Brahmer et al. 2012 24 | I | BMS-936559 | Recurrent ovarian cancer | 17 | Not reported | 6% | Not reported | Not reported |
| KEYNOTE-028 (Varga et al. 201925 | Ib | Pembrolizumab | PD-L1+recurrent ovarian cancer | 26 | 15.4 | 11.5% | 1.9 | 13.8 |
| KEYNOTE-100 (Matulonis et al. 2019; Matulonis et al. 2020)26 27 | II | pembrolizumab | Recurrent ovarian cancer (cohort A: progression-free interval 3–12 months; cohort B: progression-free interval ≥3 months) |
376 (285 cohort A; 91 cohort B) | Not reported | Cohort A: 8.1% cohort B: 9.9% |
Cohort A: 2.1 months cohort B: 2.1 months |
Cohort A: 18.7 cohort B: 17.6 |
| KEYNOTE-158 (Marabelle et al. 2020)29 | II | pembrolizumab | Advanced microsatellite instability-high/mismatch repair-deficient ovarian cancer | 15 | 13.4 | 33.3% | 2.3 | Not reached |
| UMIN000005714 (Hamanishi et al. 2015)30 | II | Nivolumab | Platinum-resistant recurrent ovarian cancer | 20 | 11.0 | 15% | 3.5 | 20.0 |
| NINJA (Omatsu et al. 2020)31 | III | Nivolumab vs gemcitabine/pegylated liposomal doxorubicin | Platinum-resistant recurrent ovarian cancer | 316 | Not reported | 8% vs 13% | 2.0 vs 3.8 | 10.1 vs 12.1 |
| Infante et al. 2016 32 | Ia | Atezolizumab | Recurrent ovarian cancer | 9 | Not reported | 22% | 2.9 | 11.3 (immune cell score 2)/17.4 (immune cell score 3) |
| JAVELIN (Disis et al. 2019)33 | Ib | Avelumab | Platinum-resistant recurrent ovarian cancer | 125 | 26.6 | 9.6% | 2.6 | 11.2 |
| JAVELIN 200 (Pujade-Lauraine et al. 2021)34 | III | Avelumab vs avelumab+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin | Platinum-resistant recurrent ovarian cancer | 566 | not reported | 3.7% vs 13.3% vs 4.2% | Avelumab vs pegylated liposomal doxorubicin: 1.9 vs 3.5 months; HR 1.68; p>0.999 | Avelumab vs pegylated liposomal doxorubicin: 11.8 vs 13.1 months; HR 1.14; p=0.8253 |
| NCT0161155835 | II | Ipilimumab | Platinum-sensitive recurrent ovarian cancer | 40 | not reported | 10.3% | − | − |
| Zamarin et al. 2020 37 | II | Nivolumab vs nivolumab+ipilimumab | Recurrent ovarian cancer | 100 | not reported | 12.2% vs 31.4% | 2 vs 3.9 months (HR 0.53) |
21.8 vs 28.1 months (HR 0.79) |
| Johnson et al. 2019 36 | I | PF-06801591 | Advanced ovarian cancer | 15 | Not reported | 20% | 5.3 | Not reached |
HR, hazard ratio; PD-L1, programmed death ligand 1.